false
0001860871
0001860871
2024-04-26
2024-04-26
0001860871
TVGN:CommonStockParValue0.0001PerShareMember
2024-04-26
2024-04-26
0001860871
TVGN:WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember
2024-04-26
2024-04-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 26, 2024
Tevogen
Bio Holdings Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41002 |
|
85-1284695 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
15
Independence Boulevard, Suite #410
Warren, New Jersey |
|
07059 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (877) 838-6436
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
TVGN |
|
The
Nasdaq Stock Market LLC |
Warrants,
each exercisable for one share of Common Stock for $11.50 per share |
|
TVGNW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
April 26, 2024, Tevogen Bio Holdings Inc. (the “Company”) issued a press release announcing certain expected pro forma combined
financial results of the Company and the Company’s wholly owned subsidiary, Tevogen Bio Inc. (“Tevogen Bio”), and certain
expected financial results of Tevogen Bio as of and for the year ended December 31, 2023. A copy of the press release is attached to
this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Tevogen
Bio Holdings Inc. |
|
|
Date:
April 26, 2024 |
By: |
/s/
Ryan Saadi |
|
Name:
|
Ryan
Saadi |
|
Title: |
Chief
Executive Officer |
Exhibit
99.1
Tevogen
Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
|
● |
Conversion
of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities. |
|
● |
The
converted common stock is included in the company’s total 165 million outstanding shares. |
|
● |
The
Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution,
and patient access. |
April
26, 2024
Warren,
N.J., Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy
biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
Dear
Fellow Stockholders:
In
anticipation of the filing of our annual financial statements, I would like to provide our investors with a few reflections on anticipated
financial results.
First,
we expect to report that as of December 31, 2023, and for year-end 2023, the liabilities and net losses of Tevogen Bio Inc were primarily
related to convertible promissory notes. Those notes were assumed and converted into shares of Tevogen Bio Holdings Inc in connection
with the business combination between Tevogen Bio Inc and Semper Paratus Acquisition Corporation that closed on February 14, 2024. We
expect to report that the net losses of Tevogen Bio Inc consisted primarily of non-cash charges related to the change in the fair value
of the convertible promissory notes, not the operating expenses of Tevogen Bio Inc, and that Tevogen Bio Inc’s operating expenses
for 2023 were $8.8 million. Due to the conversion of the convertible promissory notes, we will report that on a pro forma basis, there
are no longer any liabilities associated with convertible promissory notes, and that the non-cash charge related to the change in the
fair value of the notes has been eliminated from the pro forma condensed combined statement of operations. We anticipate disclosing that
of the $94.9 million of balance sheet liabilities that were removed by the conversion of the notes, $80.7 million were current liabilities
and $14.2 million were long-term liabilities.
Second,
I’d like to reflect on our recent leadership appointments and the newly launched initiative in Artificial Intelligence (AI). The
Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution,
and patient access. Mittul Mehta, our Chief Information Officer (CIO) and Head of Tevogen.ai, brings over 20 years of experience in information
technology and nearly a decade in senior management roles. Previously, Mr. Mehta served as Senior Vice President, Global Head of Platforms
Security, Mobility & Cloud Security at Jefferies LLC, where he played a key role in enterprise strategy. His extensive experience
across various organizations, including Avanade Inc., Macy’s Inc., MetLife Inc., and Microsoft Corporation, demonstrates his ability
to align technology with business objectives and lead teams effectively through complex projects and shifting priorities. Looking ahead,
Mr. Mehta will share his vision for AI in biotechnology and healthcare through featured speeches including at the Longwood Healthcare
Leaders Spring MIT conference and Hogan Lovells Annual Health Care AI Law and Policy Summit.
Tevogen
also appointed Tapan V. Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall Street veteran with over 25 years
of experience across key financial services industry verticals, brings broad leadership capabilities to Tevogen Bio. Most recently, Mr.
Shah was Director, Relationship Management, in Citigroup’s Client organization, where he was also a member of the Executive Office.
Prior to Citigroup, he worked in Morgan Stanley’s asset management business (MSIM) focused on Equity Strategy and Product Development.
Mr. Shah started his career in the Investment Banking Division of Goldman Sachs. In this new position, Mr. Shah will lead communications
with all financial stakeholders, including shareholders, research analysts, and investment bankers. He will also lead the M&A and
capital raising functions at Tevogen Bio.
We
believe our allogeneic, precision T cell technology platform, ExacTcellTM, represents a significant scientific breakthrough
that has the potential to develop a new class of off the shelf T cell therapeutics with diverse applications spanning virology, oncology,
and neurology.
As
I prepare to attend the Yale CEO Summit with fellow business leaders from all sectors of our economy, I thank you all for your continued
support for our shared mission for a healthier world.
Sincerely,
Ryan
Saadi
CEO,
Tevogen Bio Holdings Inc.
About
Tevogen
Tevogen
is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases,
cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes
that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science
and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual
property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted
patents and twelve pending patents, two of which are related to artificial intelligence.
Tevogen
is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch
experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that
disruptive business models are required to sustain medical innovation.
Forward
Looking Statements
This
press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding
the expected financial results of Tevogen and its subsidiary Tevogen Bio Inc. and the combined pro forma financial results of Tevogen
and Tevogen Bio Inc. as of and for the year ended December 31, 2023; the healthcare and biopharmaceutical industries; Tevogen’s
development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer
and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional
product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations
regarding Tevogen’s future clinical trials; Tevogen’s manufacturing plans; and Tevogen’s ability to generate revenue
in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,”
“expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,”
“project,” “believe,” “future,” and similar words and expressions or their opposites. These statements
are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and
are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s
control that may cause actual results, performance or achievements of the company to be materially different from the results, performance
or other expectations expressed or implied by these forward-looking statements. The expected financial information presented in this
press release is subject to completion of Tevogen’s financial closing procedures and therefore preliminary and subject to change,
and any changes could be material. Furthermore, this information does not present all information necessary for an understanding of the
financial condition as of or results of operations for the year ended December 31, 2023, of Tevogen or Tevogen Bio Inc or their combined
pro forma financial condition or results of operations. Tevogen will provide further information on its results when it files its Annual
Report on Form 10-K for the fiscal year ended December 31, 2023.
Factors
that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements
include, but are not limited to: (i) uncertainty regarding the timing and filing of Tevogen’s Annual Report on Form 10-K and related
disclosure of pro forma financial results; (ii) changes in final results arising from financial closing procedures; (iii) the effect
of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s
business relationships, operating results, and business generally; (iv) the outcome of any legal proceedings that may be instituted against
Tevogen related to the Business Combination; (v) changes in the markets in which Tevogen competes, including with respect to its competitive
landscape, technology evolution, or regulatory changes; (vi) changes in domestic and global general economic conditions; (vii) the risk
that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations;
(viii) the risk that Tevogen may not be able to develop and maintain effective internal controls; (ix) costs related to the Business
Combination and the failure to realize anticipated benefits of the Business Combination; (x) the failure to achieve Tevogen’s commercialization
and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition,
the ability of Tevogen to grow and manage growth economically and hire and retain key employees; (xi) the risk that Tevogen may fail
to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments
in unsuccessful new products and services; (xii) the ability to develop, license or acquire new therapeutics; (xiii) that Tevogen will
need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xiv) the risk
of regulatory lawsuits or proceedings relating to Tevogen’s business; (xv) uncertainties inherent in the execution, cost, and completion
of preclinical studies and clinical trials; (xvi) risks related to regulatory review, and approval and commercial development; (xvii)
risks associated with intellectual property protection; (xviii) Tevogen’s limited operating history; and (xix) those factors discussed
or incorporated by reference in Tevogen’s filings with the SEC and that that are contained in the Proxy Statement/Prospectus relating
to the Business Combination.
You
should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation
to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen
Bio Communications
T:
1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
v3.24.1.u1
Cover
|
Apr. 26, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Apr. 26, 2024
|
Entity File Number |
001-41002
|
Entity Registrant Name |
Tevogen
Bio Holdings Inc.
|
Entity Central Index Key |
0001860871
|
Entity Tax Identification Number |
85-1284695
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
15
Independence Boulevard
|
Entity Address, Address Line Two |
Suite #410
|
Entity Address, City or Town |
Warren
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
07059
|
City Area Code |
(877)
|
Local Phone Number |
838-6436
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
TVGN
|
Security Exchange Name |
NASDAQ
|
Warrants, each exercisable for one share of Common Stock for $11.50 per share |
|
Title of 12(b) Security |
Warrants,
each exercisable for one share of Common Stock for $11.50 per share
|
Trading Symbol |
TVGNW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=TVGN_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=TVGN_WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Semper Paratus Acquisiti... (NASDAQ:LGSTU)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Semper Paratus Acquisiti... (NASDAQ:LGSTU)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024